Przejdź do zawartości
Merck

In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Antimicrobial agents and chemotherapy (2009-05-20)
Kazuko Yamamoto, Katsunori Yanagihara, Kazuyuki Sugahara, Yoshifumi Imamura, Masafumi Seki, Koichi Izumikawa, Hiroshi Kakeya, Yoshihiro Yamamoto, Yoichi Hirakata, Shimeru Kamihira, Shigeru Kohno
ABSTRAKT

We evaluated the potency of garenoxacin in selecting resistant Streptococcus pneumoniae mutants by determining its mutant prevention concentration, using strains with and without topoisomerase gene mutations, and compared its potency to that of other quinolones. Garenoxacin had a significantly greater potency against pneumococci, including strains containing topoisomerase mutations. Genetic analysis of the S. pneumoniae mutants created by garenoxacin revealed that the gyrA gene was a primary target of garenoxacin.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)